Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Pancreatic Cancer: A Retrospective Study From The Najran Region Of Saudi Arabia

Pancreatic Cancer: A Retrospective Study From the Najran Region of Saudi Arabia

Ahmed M Badheeb1,2, Mohammad A Awad3, Ali G Al Masad4

  • 1Oncology, King Khalid Hospital-Oncology Center, Najran, SAU.

Cureus
|August 29, 2024

Related Experiment Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

747
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

10.5K
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
10:38

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens

Published on: February 1, 2020

7.4K

View abstract on PubMed

Summary
This summary is machine-generated.

Advanced pancreatic cancer survival is poor, especially with metastatic presentation and poor performance status. FOLFIRINOX chemotherapy offers better survival rates than gemcitabine alone for patients with pancreatic cancer.

Area of Science:

  • Oncology
  • Gastroenterology
  • Cancer Research

Background:

  • Pancreatic cancer has a low survival rate due to late diagnosis.
  • Treatment aims to extend survival and maintain quality of life.

Purpose of the Study:

  • Investigate factors affecting survival in advanced pancreatic cancer patients.
  • Evaluate treatment efficacy in a Saudi Arabian academic center.

Main Methods:

  • Retrospective chart review of 80 pancreatic cancer patients (2015-2023).
  • Analysis of clinicopathological data, therapy, response, and survival outcomes.
  • Statistical analysis using chi-squared, Kaplan-Meier, and Cox proportional hazards models.

Main Results:

  • Majority of patients (73.8%) presented with distant metastases.
Keywords:
: pancreatic cancerchemotherapygemcitabinemortality

Related Experiment Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

747
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

10.5K
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
10:38

DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens

Published on: February 1, 2020

7.4K
  • FOLFIRINOX showed better response rates than gemcitabine alone (p=0.002).
  • Initial metastasis, poor ECOG-PS (3-4), and multiple metastases were linked to worse survival (p<0.001, p=0.003, p=0.004).

    • Conclusions:

    • Metastatic presentation, poor ECOG-PS, and multiple metastases predict poor pancreatic cancer survival.
    • FOLFIRINOX as first-line therapy improves survival compared to gemcitabine alone.
    • Increased awareness and personalized oncology may enhance outcomes for pancreatic cancer.
    najran
    pancreatic ductal adenocarcinoma
    prognostic factors
    saudi arabia
    survival